Side by side
Consultation participation and their own register declarations, side by side. Counts, not judgments — participation is not influence.
Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Company · United States
NGO · Belgium
Declared costs: not declared · in the register since 2010
Medicinal products for human use · A European Health Data Space · Revision of the EU legislation on medicines for children and rare diseases
Register facts self-declared (snapshot 2 Sept 2026); cost bands are floors. Shared files are shared attention, not evidence of coordination.
Their opening passages on the files they share, verbatim and in filing order. We do not summarize, compare, or characterize positions — read them at source.
Biogen · filed 26 Apr 2021 · source
Biogen is one of the world’s leading biotechnology companies, with a focus on discovering, developing, and delivering worldwide innovative therapies for people living with serious neurological diseases. The planned initiative to evaluate the general pharmaceutical legislation is an opportunity to incorporate learnings into a future medicine regulatory framework that supports innovation and can accommodate rapid…
European Public Health Alliance (EPHA) · filed 27 Apr 2021 · source
The revision of the EU general pharmaceuticals legislation should aim to address the problems of availability, accessibility and affordability of medicines as well as to incentivise meaningful, public health needs-driven biomedical innovation. Put simply, it should serve the goal of having better and affordable medicines for those who need them.
Biogen · filed 3 Feb 2021 · source
Biogen is one of the world’s leading biotechnology companies, with a focus on discovering, developing, and delivering innovative therapies and digital solutions for people living with serious neurological diseases.
European Public Health Alliance (EPHA) · filed 3 Feb 2021 · source
EPHA welcomes the European Health Data Space as a Commission priority and is pleased that it is seen as a way to increase the ability of digital health to reduce inequalities and provide high-quality healthcare.
European Public Health Alliance (EPHA) · filed 18 Dec 2020 · source
Small biotechs, university spin-offs and other research institutions are now at the heart of pharmaceutical R&D conducting the early-stage research, financed by venture capitalists, hedge funds and private equity. Large pharmaceutical companies perform less research in-house while they scan the horizon for promising products and companies. They subsequently acquire them.
Biogen · filed 21 Dec 2020 · source
Biogen discovers, develops, and delivers innovative therapies for people living with serious neurological and neurodegenerative diseases, including rare conditions – an area to which we are strongly committed to.
2 organizations on one sheet: every file each filed on, their register declarations, and a working link to each submission. Free: we ask for your name and email, and PolicySpeak may contact you about the product (privacy policy). The per-file record stays downloadable without signing up on each file’s page.